– In its cis form, MEYD‑873 has a nanomolar affinity (K D ≈ 8 nM) for the extracellular vestibule of Nav1.7, but the photocage sterically hinders the key pharmacophore, rendering the interaction functionally silent.
If the upcoming Phase II trials confirm these signals, MEYD‑873 could become the on the market, offering clinicians a new lever to control both malignant growth and hyper‑inflammatory disease states. MEYD-873
| Indication | Rationale | Proposed Delivery | |------------|-----------|--------------------| | | Direct modulation of peripheral Nav1.7 reduces ectopic firing without systemic analgesics | Subcutaneous infusion pump + percutaneous NIR catheter | | Drug‑resistant focal epilepsy | Rapid, localized suppression of hyper‑excitable networks | Intravenous loading dose + stereotactic NIR fiber placement | | Neuro‑prosthetic control | Enables bidirectional communication: a “push” signal to augment cortical output for prosthetic actuation | Systemic dosing + wearable NIR head‑gear for on‑demand activation | | Research tool for circuit mapping | Reversible, high‑temporal‑resolution control of specific neuronal populations | Systemic or intracerebral injection + flexible NIR illumination arrays | – In its cis form, MEYD‑873 has a